Top 5 Blue Chip Stocks To Buy Right Now

When I initiated coverage on Xerox (NYSE:XRX), I concluded that the stock wasn’t dead, and in January, I opined the name was also not “dead money.” That is important to reiterate. But this once stellar blue chip has certainly fallen from grace, big time. I then told you that the company was “not dead yet.” But friends, are we approaching the death of Xerox? I mean, it has been struggling for a long time. I suggested on nice dips you could buy simply for the yield and collect the dividend, but growth was nowhere to be found. I said had in my prior work numerous times that we needed to see some improvement in the underlying metrics before I could get behind the name. Well, in the past three months, the stock has moved sideways to higher, but will there be sustained momentum? That is tough to tell, but the name has been downgraded and the most recent earnings were not great.

The truth is that performance has been pitiful of late and is the reason shares have declined. Well here, Q3 shows that there are still declining revenues. Revenue as a whole came in at $4.21 billion, and this messed estimates by $100 million. However, this was also down 5.4% year over year, continuing a string of declining quarters. In addition the degree of declining revenues seems to be picking up and this is real bad news. Of course, as I have discussed in-depth in other articles, the strong dollar has hurt companies with international businesses.

Top 5 Blue Chip Stocks To Buy Right Now: magicJack VocalTec Ltd(CALL)

Advisors’ Opinion:

  • [By Monica Gerson]

    magicJack VocalTec Ltd (NASDAQ: CALL) is projected to post its quarterly earnings at $0.30 per share on revenue of $25.00 million.

    Rentech, Inc. (NASDAQ: RTK) is estimated to post a quarterly loss at $0.08 per share on revenue of $81.02 million.

  • [By Peter Graham]

    Any smidgen of magic left in magicJack VocalTec (CALL) is vanishing quicker than street magician David Blaine can make a new quarter disappear.

    Now the former star of annoying, late-night TV commercials only wishes it could make its melting core business model reappear.

  • [By Peter Graham]

    Any smidgen of magic left in magicJack VocalTec (CALL) is vanishing quicker than street magician David Blaine can make a new quarter disappear.

    Now the former star of annoying, late-night TV commercials only wishes it could make its melting core business model reappear.

Top 5 Blue Chip Stocks To Buy Right Now: Huntington Bancshares Incorporated(HBAN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Who is at the lower-end of the range for 2016 payout ratios? We expect Zions Bancorporation, Huntington Bancshares (HBAN), andBank of America to seek the least amount of capital return in 2016 (ranging between 50-60% of estimated earnings).

Top 5 Blue Chip Stocks To Buy Right Now: Yandex N.V.(YNDX)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of Somerset Capital Management LLP’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Somerset+Capital+Management+LLP

    These are the top 5 holdings of Somerset Capital Management LLPFomento Economico Mexicano SAB de CV (FMX) – 1,268,818 shares, 36.15% of the total portfolio. Shares reduced by 9.36%Yandex NV (YNDX) – 3,352,412 shares, 25.48% of the total portfolio. Shares reduced by 3.61%ICICI Bank Ltd (IBN) – 5,074,899 shares, 13.19% of the total portfolio. Shares reduced by 11.08%Infosys Ltd (INFY) – 1,596,414 shares, 6.95% of the total portfolio. Shares reduced by 15.58%KT Corp (KT) – 1,330,431 shares, 6.41% of the

  • [By Monica Gerson]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Monday’s regular session.

    Pier 1 Imports Inc (NYSE: PIR) Dec16 5.0 Puts Sweep: 1191 @ ASK $0.80: 1354 traded vs 102 OI: $5.32 Ref
    Alcoa Inc (NYSE: AA) Jul16 9.5 Puts Sweep: 1494 @ ASK $0.13: 14k traded vs 6682 OI: $10.09 Ref
    Sarepta Therapeutics Inc (NASDAQ: SRPT) Jul16 10.0 Puts: 3536 @ ASK $0.50: 5506 traded vs 54k OI: Earnings 8/4 $22.50 Ref
    Tableau Software Inc (NYSE: DATA) Jul16 47.5 Puts Sweep: 837 @ ASK $0.30: 995 traded vs 37 OI: Earnings 8/3 $50.60 Ref
    Yandex NV (NASDAQ: YNDX) Aug16 18.0 Puts Sweep: 532 @ ASK $0.30: 2143 traded vs 78 OI: Earnings 7/28 Before Open $22.02 Ref
    Wolverine World Wide, Inc. (NYSE: WWW) Aug16 22.5 Puts: 719 @ ASK $1.35: 1032 traded vs 0 OI: Earnings 7/19 $22.22 Ref
    Conn's Inc (NASDAQ: CONN) Jan17 5.0 Puts Sweep: 605 @ ASK $0.85: 1355 traded vs 3132 OI: $7.16 Ref

    Posted-In: Huge Put PurchasesNews Options Markets

  • [By Lee Jackson]

    Yandex N.V. (NASDAQ: YNDX) is the Google of Russia. It was very bold on the growing marketplace there, and its beta tests of a new back end have been very positive and should be rolled out soon. Deutsche Bank has a $38 price target, and the consensus is $40, in U.S. dollars.

  • [By Steve Symington]

    Yandex N.V.(NASDAQ:YNDX)announced exceptional first-quarter 2017 results on Thursday, highlighted by a recent antitrust deal with Google, stabilizing market share in its core search segment, and strong growth from its various other business units.

  • [By Peter Graham]

    A long term performance chart shows Alphabet Inc being in a relatively steadyuptrend compared withsearch engine peerslike Yahoo! Inc (NASDAQ: YHOO), China basedBaidu Inc (NASDAQ: BIDU) and Russiafocused mid cap Yandex NV (NASDAQ: YNDX):

Top 5 Blue Chip Stocks To Buy Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Yesterday, after markets closed, it was announced that US Federal District Court Judge Sue Robinson ruled to issue a permanent injunction against Praluent, the PCSK9 mAb for hypercholesterolemia from partners Regeneron and Sanofi, due to infringement of patents from Amgen. The court has imposed a 30-day suspension (stay) on the injunction to allow for settlement or appeal of the District Court decision. Sanofi and Regeneron have announced their intent to appeal the ruling to the US Court of Appeals for the Federal Circuit (CAFC). The injunction decision is consistent with our counter-consensus published views communicated on 25 January 2016 (“Downgrade to Sell on evidence of likely infringement of Amgen’s PCSK9 patents”) and subsequently. Based on consultation with expert legal counsel, we now put >75% probability Amgen will prevail on appeal and/or Praluent is ultimately removed from the US market, and/or Amgen achieves a settlement substantially in its favor. We currently model $3.3 bn in non-risk-adjusted 2022E US revenues for Praluent, while consensus models $1.2 bn in 2022E US revenues. We reiterate our view from 25 January 2016 to preferentially own Amgen, The Medicines Company (MDCO) (Buy), and Alnylam (ALNY) (Buy) over Regeneron for exposure to PCSK9 inhibitor market dynamics as outcomes trials approach.

  • [By Lisa Levin]

    Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares shot up 53 percent to $114.87 after the company impressed investors with encouraging data from a phase 3 clinical trial. Alnylam, a company dedicated towards treating a wide range of debilitating diseases through ribonucleic acid (RNA) interference (RNAi) therapeutics, said after Tuesday's market close that a phase 3 study called APOLLO met its primary efficacy endpoint and all secondary endpoints.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) jumped as much as 14.5% today after announcing earnings after the bell yesterday. As a development-stage biotech, it wasn’t the revenue or the earnings that caused the spike, but the progression of Allnylam’s pipeline.

  • [By Cory Renauer]

    Treating diseases that have a genetic component by altering the expression of the responsible genes is a promising new field of medicine, but it has been much less straightforward than biopharmaceutical companies had expected. Two contenders in this area, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS), saw a mix of setbacks and success in 2016.

Top 5 Blue Chip Stocks To Buy Right Now: Molson Coors Brewing Company(TAP)

Advisors’ Opinion:

  • [By ]

    Not to be outdone, industry behemoth Molson Coors Brewing Co. (NYSE:TAP) announced it might soon throw its hat into the ring. Think about it one of the most recognizable big brewers in the country will soon look to expand into the cannabis business.

  • [By Mark Fritz]

    Price Target: 116 euros.

    Molson Coors Brewing Co (NYSE: TAP): Sell.
    Price Target: $78.

    Boston Beer Company Inc (NYSE: SAM): Sell.

    Price Target: $124.

  • [By Jayson Derrick]

    The Canadian beer market, much like the American beer market, is seeing a growth in craft products at the expense of established players. And one of the biggest established beer makers in Canada is Molson Coors Brewing Co (NYSE: TAP), Bereneberg’s Javier Gonzalez Lastra and Matt Reid commented in an initiation note.

  • [By WWW.THESTREET.COM]

    In the past, Cramer has been a fan of both Constellation as well as Molson Coors (TAP) , which was able to snap up all the Miller and Coors brands last year for $12 billion. That deal is expected to boost Molson’s earnings by 25% this year.

  • [By Seth McNew]

    It isn’t the only beer company facing hardships now, and in fact, it’s still growing faster than its largest competitors — Sam Adams parent Boston Beer (NYSE:SAM) and Molson Coors Brewing (NYSE:TAP). Boston Beer’s total sales fell 5.4% in 2016, year over year, and Molson Coors’ sales were down 2.3%.

Leave a Reply

Your email address will not be published. Required fields are marked *